Antibody Name: MikB1
References: Hakimi, J., Ha, V.C., Lin, P., Campbell, E., Gately, M.K., Tsudo, M., Payne, P.W., Waldmann, T.A., Grant, A.J., Tsien, W. and Schneider, W.P. "Humanized MikB1, A humanized antibody to the IL-2 receptor B-chain that acts synergistically with humanized anti-TAC" J. Immunol. (1993) 151: 1075-1085.
Donor Antibody: mouse
Acceptor Antibody: Human IgG1 | k
Antigen: B-subunit (p70) of human IL-2R (Tac) (CD122)
Laboratory: Hoffmann-LaRoche, NJ; PDL, CA; Kyoto-Katsura Hospital, Japan; NCI, MD
Design: Choose homologous FRs from same antibody. Model mouse Fv regions to identify residues which make contact with CDRs. Change atypical residues to human. Two versions made.
Frameworks: VH LAY | VL LAY
CDRs: All 6 VH and VL, Kabat Definition.
Backmutations: Back to human consensus (fortuitously mouse in bold)
VH A1E G82(b)S V86D S87T
VL V13A L42K
Best version HuMikB1-1 Back to mouse
VH T28S F29V S30T V37I V48L A49G F67L R71K N72D D73N L78V L80F
VL Q3V M4L K39R K45R D70S F71Y
Binding: Equivalent to mouse in competition binding. Version with most backmutations was better at blocking IL-2 binding and acting synergistically with anti-Tac.
Expression: Sp2/0
Comment: none
Clinical Indication: Graft-versus-host disease (GVHD), autoimmune diseases and prevention of allograft rejection in conjunction with HAT (humanised anti-Tac).

explanation of symbols and abbreviations

José Saldanha © 1997-8. Birkbeck College, London WC1E 7HX.